Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03056053 · ClinicalTrials.gov registry record · Phase 2
Study to Validate the Questionnaire Called IDSIQ™ in Patients With Insomnia Disorder
A Phase 2 study, sponsored by Idorsia Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 113
- Enrollment target
NCT03056053 is a Phase 2 study that has completed, run by Idorsia Pharmaceuticals. The registered enrollment target is 113 participants.
The verdict
NCT03056053, a Phase 2 study, has completed, sponsored by Idorsia Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 113 participants
- Enrollment target
Study Summary
The main study objective is to assess the content validity and the psychometric characteristics of the Insomnia Daytime Symptoms and Impacts Questionnaire™ (IDSIQ™).
Interventions
- DRUG Zolpidem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 113 participants |
| Start Date | 2017-02-15 |
| Est. Completion | 2017-05-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03056053
The ClinicalTrials.gov registry entry for NCT03056053 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 113 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Idorsia Pharmaceuticals, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Zolpidem is the first listed.
NCT03056053 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03056053 about?
NCT03056053 is a clinical study titled "Study to Validate the Questionnaire Called IDSIQ™ in Patients With Insomnia Disorder". The main study objective is to assess the content validity and the psychometric characteristics of the Insomnia Daytime Symptoms and Impacts Questionnaire™ (IDSIQ™).
What is the current status of trial NCT03056053?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 113 participants. The study started on 2017-02-15. Estimated completion is 2017-05-05.
What interventions are being tested in trial NCT03056053?
The interventions under investigation include: Zolpidem (DRUG).
Who is sponsoring clinical trial NCT03056053?
This trial is sponsored by Idorsia Pharmaceuticals, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.